A practical reference on c-Met: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-09. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
Formation of excessive scar tissue is thus prevented. The combination of silicone gel sheeting and compression therapy has been proven to be more effective than using the sheet alone. Patients who find the non-invasive treatments ineffective may choose to undergo invasive treatments such as intralesional injections of corticosteroids, surgical excision of the scars, and radiotherapy.
== Medical uses == Doxepin is used as a pill to treat major depressive disorder, anxiety disorders, and chronic hives, and for short-term help with trouble remaining asleep after going to bed (a form of insomnia). As a cream it is used for short-term treatment of itchiness caused by atopic dermatitis or lichen simplex chronicus.
The World Health Organization (WHO) recommends two doses of vaccine for all children. In countries with a high risk of disease the first dose should be given around nine months of age. Otherwise it can be given at twelve months of age. The second dose should be given at least one month after the first dose. This is often done at age 15 to 18 months. After one dose at the age of nine months 85% are immune, while a dose at twelve months results in 95% immunity. In the United States, the Centers for Disease Control and Prevention (CDC) recommends that children aged six to eleven months traveling outside the United States receive their first dose of MMR vaccine before departure and then receive two more doses; one at 12–15 months (12 months for children in high-risk areas) and the second as early as four weeks later. Otherwise the first dose is typically given at 12–15 months and the second at 4–6 years. In the UK, the National Health Service (NHS) recommendation is for a first dose at around 13 months of age and the second at three years and four months old. Health Canada recommends that children traveling outside North America should receive an MMR vaccine if they are aged six to 12 months. However, after the child is 12 months old they should receive two additional doses to ensure long-lasting protection.
Sources: en.wikipedia.org
== Insulin pen == Reith's daughter was diagnosed with Type 1 diabetes when she was four. When her daughter was five, they travelled from Glasgow to London by train as the family relocated to Scotland, and Reith had to use the public toilets at Euston Station to inject her with insulin, a process involving drawing the insulin from a glass phial using a steel hypodermic syringe, which would later require being boiled to re-sterilise it. The inconvenience, discomfort and hygiene implications of this situation led her to conceive a reusable, cartridge-based system. She developed the idea at the Southern General Hospital from 1978 with her colleague and fellow physician John Ireland, and John Paton, a bioengineer recruited at the University of Glasgow's Department of Clinical Physics and Bio-Engineering, for the project. The invention was announced in a January 1981 paper in The Lancet by Reith alongside Ireland, Paton and Margaret Wilson, also of Southern General. It described the use of the prototype, based on a device known as the Becton-Dickinson 'Plastipak' self-contained insulin syringe, by seven patients aged from 8 to 49. Further clinical trials commenced the same year, using 100 pens and 5,000 insulin cartridges funded by Diabetes UK. Within two years the world's first insulin pen, branded "Penject", entered general use.
== Medical uses == Trifluridine eye drops are used for the treatment of keratitis and keratoconjunctivitis caused by the herpes simplex virus types 1 and 2, as well as for prevention and treatment of vaccinia virus infections of the eye. A Cochrane Systematic Review showed that trifluridine and aciclovir were a more effective treatment than idoxuridine or vidarabine, significantly increasing the relative number of successfully healed eyes in one to two weeks.
==== Delivery mechanisms ==== To achieve the clinical potential of RNAi, siRNA must be efficiently transported to the cells of target tissues. However, there are various barriers that must be fixed before it can be used clinically. For example, "naked" siRNA is susceptible to several obstacles that reduce its therapeutic efficacy. Additionally, once siRNA has entered the bloodstream, naked RNA can be degraded by serum nucleases and can stimulate the innate immune system. Due to its size and highly polyanionic (containing negative charges at several sites) nature, unmodified siRNA molecules cannot readily enter the cells through the cell membrane. Therefore, artificial or nanoparticle encapsulated siRNA must be used. If siRNA is transferred across the cell membrane, unintended toxicities can occur if therapeutic doses are not optimized, and siRNAs can exhibit off-target effects (e.g. unintended downregulation of genes with partial sequence complementarity). Even after entering the cells, repeated dosing is required since their effects are diluted at each cell division. In response to these potential issues and barriers, two approaches help facilitate siRNA delivery to target cells: lipid nanoparticles and conjugates.
Sources: en.wikipedia.org
Booker Brooks (George Clooney) – The original foreman at Wellman. Booker wasn't always taken seriously by the workers, but compared to their future boss, Roseanne and the others appreciate him more. He dated Jackie for a while, and they tried to keep it a secret. He set the quotas at Wellman at 5,500, much lower than the 8,000 set by their next boss Keith Faber (Fred Thompson). Vonda Green (Charlayne Woodard, credited as Charlaine Woodard)- Spirited and perky friend of Jackie and Roseanne, also has a great singing voice. Sylvia Foster (Anne Faulkner)- Older Wellman employee working there since the late 1950s, she occasionally hangs out with Jackie, Roseanne, and the rest of the gang at the Lobo. Has a husband named Joe who is hard of hearing. Juanita Herrara (Evelina Fernandez)- Hispanic co-worker who after leaving Wellman with the rest of the gang opens a successful small business in Lanford with her husband Emilio and their teenage son. Meg Wellman (Debra Mooney) – Owner of the Wellman factory, who believes she and Roseanne are good friends. Unaware she's getting their names wrong, she comically refers to Roseanne as "Roxanne Conway" and Jackie as Janet. Accidentally hits Roseanne's car with her car in one episode.
== History == The drug was invented by Ciba-Geigy (now Novartis) in the early 1980s and sold to Jenner Biotherapies in the 1990s. In 2003, IDM Pharma bought the rights and developed it further. IDM Pharma was acquired by Takeda along with mifamurtide in June 2009. Mifamurtide had already been granted orphan drug status by the U.S. Food and Drug Administration (FDA) in 2001, and the European Medicines Agency (EMA) followed in 2004. It was approved in the 27 European Union member states plus Iceland, Liechtenstein, and Norway by a centralized marketing authorization in March 2009. The drug was denied approval by the FDA in 2007. Mifamurtide has been licensed by the EMA since March, 2009.
Gabe Logan Newell (born November 3, 1962), known by his nickname Gaben, is an American video game developer and businessman who is the co-founder and president of the video game company Valve. Newell was born in Aspen, Colorado, and grew up in Davis, California. He attended Harvard University in the early 1980s but dropped out to join Microsoft, where he helped create the first versions of the Windows operating system. He also led development on a port of the game Doom for Windows 95. In 1996, Newell and Mike Harrington left Microsoft to found Valve and fund the development of their first game, Half-Life (1998). After the success of Half-Life, Harrington sold his stake in Valve to Newell and left in 2000. Newell led development of Valve's digital distribution service, Steam, which launched in 2003 and controlled most of the market for downloaded PC games by 2011. Forbes estimated that Newell owned at least half of Valve as of 2025. He is also the owner of the marine research organization Inkfish, the neuroscience company Starfish Neuroscience, and the custom yacht manufacturer Oceanco. Newell has been estimated as one of the wealthiest people in the United States and the wealthiest person in the video games industry, with an estimated net worth of $11 billion as of 2025.
The five other countries, including the second and third largest beef producers, France and the United Kingdom, respectively, permitted their use. This had resulted in disputes, with countries that had no prohibitions arguing that the restrictions by the others acted as non-tariff trade barriers. In response to the public outcry, in combination with the discovery that DES was a teratogen, in 1980 the EU began to issue regulations, beginning with prohibiting the use of stilbenes and thyrostatics by the European Community Council of Agriculture Ministers in 1980, and commissioning of a scientific study into the use of estradiol, testosterone, progesterone, trenbolone, and zeranol in 1981. The European Consumers' Organisation (BEUC) lobbied for a total ban upon growth hormones, opposed, with partial success, by the pharmaceutical industry. (In 1987 the European Federation of Animal Health (FEDESA), formed to represent, amongst other things, companies that manufactured growth hormones.) Neither European farmers nor the meat processing industry took a stance on the matter. With the help of the BEUC consumer boycotts of veal products, sparked by the Italian scandals and similar reports in France and Germany, spread across the EU, causing companies such as Hipp and Alete to withdraw their veal products, while veal prices dropped in France, Belgium, West Germany, Ireland, and the Netherlands. Because of the fixed purchases guaranteed by the EU's Common Agricultural Policy, ECU 10 million came out of the EU budget.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.